Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Novartis wins FDA’s breakthrough tag for lung cancer hopeful

Written by: | no-reply@reuters.com | Dated: Friday, September 6th, 2019

 

ZURICH (Reuters) – Novartis has secured the U.S. Food and Drug Administration’s Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.

 

Reporting by John Miller; Editing by Michael Shields and David Goodman

 

Reuters source:

https://www.reuters.com/article/us-novartis-breakthrough/novartis-wins-fdas-breakthrough-tag-for-lung-cancer-hopeful-idUSKCN1VR0HG

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom